CFAP46

Across TCGA pan-cancer cohorts, CFAP46 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CFAP46 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher CFAP46 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CFAP46 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, BLCA, and UCEC are the cancer types where CFAP46 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
BLCA	OS	Median	All	0.063	0.688	<.001	24	view →
UCEC	DFS	Median	All	0.907	0.605	.005	18	view →
HNSC	OS	Median	All	0.206	0.606	.008	15	view →
LIHC	DFS	Median	All	0.099	0.543	<.001	13	view →
STAD	OS	Median	III,IV	0.164	0.635	<.001	12	view →
COAD	OS	Median	II,III,IV	0.252	0.694	.003	8	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CFAP46–THYM (OS)

Open the THYM breakdown →